Anavex Encouraged by New Sigma-1 Receptor Study That May Explain Therapeutic Efficacy of ANAVEX 2-73 for Alzheimer’s Disease

New York, NY — October 22, 2013 — Anavex Life Sciences Corp. (“Anavex” or the “Company”) (OTCQB: AVXL) today announced that the current issue of the peer-reviewed scientific journal PLOS ONE explains that sigma-1 receptor (Sig-1R) activity is involved in cellular survival by regulating and stabilizing a key cell stress sensor.  These findings may explain…